Scarica l'app Stockscreener
56.60
3.44%
1.88
Pre-mercato:
56.85
0.25
+0.44%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol-Myers Squibb Co (BMY) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study - Yahoo Finance
Bristol Myers Squibb vs Pfizer Dividend Stock Comparison 2026News and Statistics - IndexBox
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? - The Motley Fool
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
BMY Collaborates with Arcus Biosciences on Clinical Trial for Ca - GuruFocus
Bristol-Myers Squibb stock (US1078421011): modest move as oncology data and institutional flows draw - AD HOC NEWS
Westpac Banking Corp Purchases 46,386 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb and SystImmune announce phase 3 results for antibody-drug conjugate - PMLiVE
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? - The Motley Fool
Bank of New York Mellon Corp Has $1.32 Billion Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): options activity spikes as new cancer trial data - AD HOC NEWS
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks - AOL.com
Bristol-Myers Squibb’s Italian Anticoagulant Study: Real-World Signals for BMY Investors - TipRanks
BMS-Hengrui deal strikes panic in Washington - BioWorld News
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors (NYSE:BMY) - Seeking Alpha
BMY: Positive Interim Results for Bristol Myers' Iza-bren in Can - GuruFocus
Bristol-Myers Squibb CoIzalontamab Brengitecan Shows Significant OS And PFS Improvements In TNBC And ESCC - TradingView
Assessing Bristol Myers Squibb (BMY) Valuation As Shares Track Mixed Returns And Earnings Outlook - Yahoo Finance
ASCO: Bristol Myers’ $800M bispecific ADC aces China breast cancer study, putting TROP2 drugs on notice - Fierce Biotech
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Big Pharma makes ‘creative effort’ to fold Chinese assets into pipelines - BioSpace
Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath - NAI500
Bristol Myers' Growth Portfolio Just Overtook The Legacy One - Seeking Alpha
Bristol-Myers Squibb Co (BMY) Shares Fall 3.9% -- What GF Score of 77 Tells Investors - GuruFocus
Bristol Myers Squibb Co. stock underperforms Monday when compared to competitors - MarketWatch
Bristol Myers Squibb slips as investors weigh long-term pricing and patent-cliff risks despite FDA review news - Quiver Quantitative
Jiangsu Hengrui Pharmaceuticals stock (CNE0000014X5): focus on Bristol Myers deal and China A-share - AD HOC NEWS
Bristol Myers Squibb CEO on cancer developments in the pipeline - CNBC
Cullen Enhanced Equity Income Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Full Transcript: Bristol-Myers Squibb Q1 2026 Earnings Call - Benzinga
BioNTech (BNTX) and BMS show high NSCLC response rates with pumitamig - Stock Titan
BMY: FDA Reviews Camzyos for Adolescent Hypertrophic Cardiomyopa - GuruFocus
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1 - Yahoo Finance
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma - BioSpace
FDA accepts Bristol Myers Squibb adolescent oHCM application By Investing.com - Investing.com Canada
FDA accepts Bristol Myers Squibb adolescent oHCM application - Investing.com
Sfmg LLC Decreases Stake in Bristol Myers Squibb Company $BMY - MarketBeat
US big pharma vents over Australia’s drug pricing and approvals - AFR
Peapack Gladstone Financial Corp Has $24.27 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Nomura Asset Management Co. Ltd. Decreases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
MUFG Securities EMEA plc Raises Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
BioNTech SE stock (US09075V1026): ASCO lung cancer data with Bristol Myers Squibb puts oncology pipe - AD HOC NEWS
Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 10.32% Potential Upside Amidst Healthcare Innovation - DirectorsTalk Interviews
Encouraging efficacy data for BioNTech and BMS’s pumitamig shown at ASCO - The Pharma Letter
Black Swift Group LLC Purchases New Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY: Promising Phase 2 Results for Pumitamig in Lung Cancer Trea - GuruFocus
BMY Shows Promising Results in Lung Cancer Trial - GuruFocus
Railway Pension Investments Ltd Has $63.89 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Impact Partnership Wealth LLC - MarketBeat
ASCO: In next-gen IO race, BioNTech/BMS and Pfizer are divided on overall survival approach - Fierce Biotech
Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial - The Manila Times
BioNTech and Bristol Myers Squibb Announce Promising Interim Data for Pumitamig Combined with Chemotherapy in First-Line Non-Small Cell Lung Cancer at ASCO 2026 - Quiver Quantitative
Experimental BioNTech lung cancer drug shows high responses in early trial - Stock Titan
Norges Bank Acquires Shares of 36,100,698 Bristol Myers Squibb Company $BMY - MarketBeat
Eurizon Capital SGR S.p.A. Acquires New Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company stock (US0897961004): ASCO 2026 mezigdomide data in focus after Phase 3 - AD HOC NEWS
Positive Data for Mezigdomide Boosts Bristol Myers Squibb (BMY) and C4 Therapeutics (C FOUR) - GuruFocus
Bristol Myers Squibb (BMY) Reports Positive Results for Mezigdom - GuruFocus
Bristol Myers unveils data for one of its next-gen blood cancer drugs - BioPharma Dive
Texas comptroller recommends Bristol Myers Squibb's $1B manufacturing plant for tax break - KHOU
Bristol-Myers multiple myeloma data boosts C4 (BMY:NYSE) - Seeking Alpha
1.38%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):